Allergy Therapeutics (LON:AGY) Releases Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) announced its earnings results on Monday. The company reported GBX (0.23) ($0.00) EPS for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%.

Allergy Therapeutics Trading Down 8.2 %

Allergy Therapeutics stock opened at GBX 5.92 ($0.08) on Wednesday. The stock has a 50-day moving average price of GBX 6.57 and a 200 day moving average price of GBX 5.92. Allergy Therapeutics has a 52 week low of GBX 2.65 ($0.03) and a 52 week high of GBX 8 ($0.10). The stock has a market cap of £290.97 million, a PE ratio of -5.71, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.